Phase II Trial of RAD001 in Refractory Colorectal Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentCompleted18 and overOtherCRAD0012467
Swedish Cancer Institute 05128, NCT00337545

Trial Description


Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Further Study Information

Study is completed and closed.

Eligibility Criteria

Inclusion Criteria:

  • Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
  • Measurable disease
  • ECOG 0-2

Exclusion Criteria:

  • CNS disease
  • Chemotherapy or radiotherapy < 4 weeks prior
  • Active bleeding diathesis

Trial Contact Information

Trial Lead Organizations/Sponsors

Swedish Cancer Institute at Swedish Medical Center - First Hill Campus

  • Novartis Pharmaceuticals Corporation
Philip J. Gold, Principal Investigator

Link to the current record.
NLM Identifier NCT00337545 processed this data on February 27, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to